REPL - Replimune soars 108% on BLA resubmission acceptance of melanoma asset
2025-10-20 09:00:49 ET
More on Replimune Group
- Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating
- Replimune Group: The Prospects For FDA Approval After Rejection
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune cut to Underweight at J.P. Morgan on further headline risk
- Replimune down amid uncertainty over accelerated approval